Top Markets
Coin of the day
GENinCode plc GENinCode plc

GENinCode plc

GENI
株式のランク #41235
GENinCode Plc specializes in the creation and commercialization of advanced... GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
株価
$0.01224631
時価総額
$34.25K
変化(1日)
0.00%
変化(1年)
-39.87%
GB
取引 GENinCode plc (GENI)

カテゴリー

GENinCode plc(GENI)の発行済株式数
August 2026 時点の発行済株式数 0
GENinCode plc の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
GENinCode plc(GENI)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数
企業 発行済株式数
371.00M -
US
705.30M -
US
- -
CN
143.28M -
US
80.10M -
US